Daiken Biomedical Co., Ltd.

As of June 30, 2026, Daiken Biomedical Co., Ltd. carries a market capitalization of 14.70B, placing it among publicly traded companies globally. Its enterprise value stands at 9.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Daiken Biomedical Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Daiken Biomedical Co., Ltd. has 810.02M shares outstanding.

As of June 30, 2026, Daiken Biomedical Co., Ltd. trades at a trailing price-to-earnings ratio of 32.74. The price-to-sales ratio is 6.36, and the price-to-book ratio stands at 3.02.

As of June 30, 2026, Daiken Biomedical Co., Ltd. trades at an EV/EBITDA multiple of 23.83 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Daiken Biomedical Co., Ltd. trades at an EV/FCF ratio of 36.33, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 9.56B versus a market cap of 14.70B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Daiken Biomedical Co., Ltd. maintains a current ratio of 4.75, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.42, indicating elevated leverage, while an interest coverage ratio of 196.02 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Daiken Biomedical Co., Ltd. posted a return on equity (ROE) of 14.21, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.82 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.81, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.97, useful for judging operating efficiency across full business cycles. The company generates approximately 37.68M in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.95 indicates how many times Daiken Biomedical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Daiken Biomedical Co., Ltd. recorded 123.76M in income tax expense. That works out to an effective tax rate of 22.55, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 548.72M, leaving 424.96M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Daiken Biomedical Co., Ltd.'s stock has declined approximately 13.77% over the past 52 weeks. The 50-day moving average sits at 16.41, while the 200-day moving average is 18.80.

Over the twelve months ended June 30, 2026, Daiken Biomedical Co., Ltd. generated 2.19B in revenue and converted that into 424.96M in net income, yielding earnings per share of 0.55. EBITDA reached 401.07M, while operating income came in at 393.93M.

As of June 30, 2026, Daiken Biomedical Co., Ltd. holds 5.26B in cash and equivalents against 118.07M in total debt, resulting in a net debt position of -5.16B. Total book value stands at 4.87B, with working capital of 4.73B providing operational flexibility.

Daiken Biomedical Co., Ltd. produced 262.60M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.06M in capital expenditures, free cash flow totaled 261.54M - equivalent to 0.34 per share.

Over the twelve months ended June 30, 2026, Daiken Biomedical Co., Ltd. posted a gross margin of 61.79, reflecting its pricing power and cost economics. The operating margin of 18.02 and net profit margin of 19.44 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Daiken Biomedical Co., Ltd. paid dividends of 0.71 per share. The dividend payout ratio of 128.54 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.88, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -25.72, meaning Daiken Biomedical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Daiken Biomedical Co., Ltd.'s most recent stock split took place on January 19, 2026 with a 1:10 split ratio.

As of June 30, 2026, Daiken Biomedical Co., Ltd. has an Altman Z-Score of 8.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.